| |
Tuesday, June 24, 2025 | 1pm ET / 11am PT Join us for this one hour deep dive with a panel of experts and industry leaders to gain valuable insights and guidance on diagnostic and precision medicine testing. Register now. 
|
|
Today’s Big NewsJun 20, 2025 |
|
Wednesday June 25, 2025 | 11am ET / 8am PT In this webinar, experts reveal how structured terminology and Real-World Data normalization are transforming patient identification and feasibility — slashing screen failure rates, accelerating site selection, and finally delivering measurable ROI on data spend. Register now. 
|
|
| By Nick Paul Taylor The Alliance for Regenerative Medicine has voiced deep disappointment about reports that the FDA has put the director of its cell and gene therapy office on administrative leave and escorted her out of the agency. |
|
|
|
By Fraiser Kansteiner In the wake of Robert F. Kennedy Jr.’s abrupt revamp of the CDC’s Advisory Committee on Immunization Practices, details from the panel’s planned meeting next week are confirming many industry watcher’s concerns about potential vaccine meddling by the Trump administration. |
By Zoey Becker The company and ad agency 21Grams explained how to approach comedy in drug advertising during a session at this year’s Cannes Lions festival called "Laughing at Doom: Using Humor to Talk about Illness/Hellscapes." |
By Conor Hale The announcements come in the lead up to the annual scientific sessions of the American Diabetes Association, being held this weekend in Chicago. |
|
Tuesday, June 26, 2025 | 2:30pm ET / 11:30am PT Too many with treatment-resistant depression go undiagnosed and untreated. Join this webinar to see how AI and Real-World Data can transform detection, access, and outcomes in mental health. Register now. 
|
|
By Gabrielle Masson,Darren Incorvaia Biotech has always been a little unconventional, but, as the industry’s bear market drags on, efforts to stay afloat are reaching a whole new level. |
By Kevin Dunleavy Among its positive recommendations this month, Europe’s CHMP has endorsed marketing authorization for ExCellThera’s Zemcelpro. The medicine is a stem cell transplant treatment for adults with blood cancers that require an allogeneic hematopoietic stem cell transplantation after myeloablative conditioning for whom no other type of suitable donor cells is available. |
By James Waldron Prothena is laying off almost two-thirds of its workforce as the Irish biotech navigates the fallout from giving up on its failed amyloidosis drug. |
By Conor Hale Jim Alecxih was most recently chief of the AI diagnostic company DH Medical, and has held roles at multiple medtechs throughout his career, including at Intuitive Surgical as a U.S. sales VP. |
By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Zoey Becker,Kevin Dunleavy In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. |
By Nick Paul Taylor The FDA has stopped new clinical trials that export American citizens’ living cells from the U.S. to “China and other hostile countries for genetic engineering and subsequent infusion” back into American patients. |
By Angus Liu AstraZeneca has penned a drug discovery pact focused on chronic diseases with China's CSPC Pharma. The FDA has halted new trials that export U.S. individuals' living cells to China. Chinese regulators are proposing to shorten clinical trial review times for novel medicines. And more. |
By Darren Incorvaia,Zoey Becker BMS didn’t want to choose between clinical expertise and financial know-how when selecting a new strategy leader. The Big Pharma has hired physician-turned-analyst Chris Shibutani, M.D., as executive vice president and chief strategy officer. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," AbbVie’s Daejin Abidoye, M.D., joins us to discuss the future of antibody drug conjugates. |
|
|---|
|
|
|
Patients need innovative treatments to treat diseases and save lives, but today’s biopharmaceutical development and manufacturing environment presents multiple challenges for biopharma companies. Access this valuable resource for key insights on navigating the complex road to market, including quality standards, regulatory requirements, supply-chain disruptions, and more. 
|
|
Executive Summary Biotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster. Sponsored by: IQVIA Laboratories |
Whitepaper We analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
